WallStSmart
NTRA

Natera Inc

NASDAQ: NTRA · HEALTHCARE · DIAGNOSTICS & RESEARCH

$194.75
-2.71% today

Updated 2026-04-29

Market cap
$27.81B
P/E ratio
—
P/S ratio
12.06x
EPS (TTM)
$-1.52
Dividend yield
—
52W range
$132 – $256
Volume
1.3M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Natera Inc (NTRA) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$194.75
Consensus
$259.07
+33.03%
2030 Target
—
—
DCF
—
—
14 analysts:
8 Buy1 Hold0 Sell

Management guidance

No specific CEO revenue guidance found in research data. Latest analyst consensus (as of March 2026) projects FY2026 revenue of $2.73B (+18.16% growth) and FY2027 revenue of $3.27B (+20.00% growth). Management has emphasized record Signatera growth and commercial launches (Zenith Genomics) but has not provided explicit 2026-2030 targets in the available documents.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$748.73
—
Base case (2030)
$457.56
—
Bear case (2030)
$311.97
—

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)
Revenue$1.1B$1.7B$2.3B$2.7B$3.3B$4.1B$5.2B
Revenue growth—56.7%35.9%18.2%20.0%25.4%27.8%
EPS$-3.79$-1.53$-1.52$-1.90$-0.36$0.85$2.10
P/S ratio———12.0x12.0x12.0x12.0x
Implied price———$228.78$291.17$353.57$457.56

Catalysts & risks

Growth catalysts
+ Signatera MRD test expansion across oncology indications (breast, colorectal, bladder, head/neck cancer); FDA approvals and reimbursement decisions could unlock significant revenue uplift
+ Zenith Genomics commercial launch for rare disease diagnosis and expanded rare disease footprint; partnership with MyOme for long-read methylation analysis
+ SINERGY trial success in head/neck cancer and MRD-guided treatment protocols; clinical validation expanding addressable market across multiple cancer types
+ AI/machine learning integration with NVIDIA partnership for multi-modal AI foundation models in precision medicine; competitive differentiation and pricing power
Key risks
- Reimbursement and payer adoption uncertainty; Signatera and newer tests dependent on CPT codes, insurance coverage, and positive health economics validation
- High cash burn despite growth; operating margin is -13.27% and company still unprofitable (EPS -$1.52 TTM); path to profitability delayed if growth slows
- Insider selling pressure; multiple insider transactions in Q1 2026 (CEO, CFO, Chairman, directors) at $186-$206 range signal potential confidence concerns at current valuations
- Valuation compression risk; P/S ratio of 12.59x is elevated vs. peers; stock has declined 20% from 52-week high; growth must accelerate to justify premium multiples
- Competition intensifying from larger diagnostics platforms (Quest, LabCorp, IQVIA) entering oncology/MRD space; market share concentration risk

Methodology

Natera Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 14 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.